RJA
OCUL icon

Raymond James & Associates’s Ocular Therapeutix OCUL Stock Holding History

Raymond James & Associates’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.24M Sell
142,108
-21,300
-13% -$176K ﹤0.01% 2553
2024
Q2 		$1.12M Sell
163,408
-31,625
-16% -$195K ﹤0.01% 2553
2024
Q1 		$1.77M Buy
195,033
+66,021
+51% +$469K ﹤0.01% 2239
2023
Q4 		$575K Buy
129,012
+8,451
+7% +$25K ﹤0.01% 2866
2023
Q3 		$379K Buy
120,561
+73,324
+155% +$300K ﹤0.01% 3052
2023
Q2 		$244K Sell
47,237
-1,820
-4% -$10.8K ﹤0.01% 3374
2023
Q1 		$259K Buy
49,057
+10,587
+28% +$50.3K ﹤0.01% 3337
2022
Q4 		$108K Sell
38,470
-18,955
-33% -$62.8K ﹤0.01% 3627
2022
Q3 		$238K Buy
57,425
+5,748
+11% +$29K ﹤0.01% 3331
2022
Q2 		$208K Sell
51,677
-2,422
-4% -$9.15K ﹤0.01% 3488
2022
Q1 		$268K Buy
54,099
+246
+0.5% +$1.36K ﹤0.01% 3485
2021
Q4 		$375K Sell
53,853
-39,898
-43% -$310K ﹤0.01% 3301
2021
Q3 		$938K Buy
93,751
+29,818
+47% +$335K ﹤0.01% 2619
2021
Q2 		$907K Buy
63,933
+4,279
+7% +$65K ﹤0.01% 2653
2021
Q1 		$979K Buy
59,654
+1,610
+3% +$31K ﹤0.01% 2529
2020
Q4 		$1.2M Sell
58,044
-35,341
-38% -$525K ﹤0.01% 2217
2020
Q3 		$711K Buy
93,385
+2,855
+3% +$23.7K ﹤0.01% 2389
2020
Q2 		$754K Buy
90,530
+26,855
+42% +$178K ﹤0.01% 2334
2020
Q1 		$315K Buy
+63,675
New +$314K ﹤0.01% 2733

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Raymond James & Associates's OCUL Position: Q3 2024 in Review

Raymond James & Associates reduced its Ocular Therapeutix (OCUL) stake by 13% in Q3 2024, selling an estimated $176K and leaving 142,108 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2553.

Raymond James & Associates first reported a position in OCUL in Q1 2020 and has held it in 19 quarters since. The position peaked at $1.77M in Q1 2024. 168 funds tracked by Wall St. Rank hold OCUL as of Q3 2024.

  • Raymond James & Associates held 142,108 shares of Ocular Therapeutix worth $1.24M as of Q3 2024.
  • Raymond James & Associates sold 21,300 Ocular Therapeutix shares in Q3 2024, an estimated $176K.
  • Ocular Therapeutix made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2553 holding.
  • Raymond James & Associates first reported a position in Ocular Therapeutix in Q1 2020 and has held it in 19 quarters since.
  • Raymond James & Associates's Ocular Therapeutix position peaked at $1.77M in Q1 2024.
  • 168 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.